Inmune Bio, Inc.
Ebstrocel™
RDEB
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on Ebstrocel™ for RDEB is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 12h ago
“The Company also intends to use the MHRA feedback to inform future interactions with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) with additional filings planned in late 2026 or early 2027, subject to ”